In a report released today, Gena Wang from Barclays maintained a Buy rating on Vir Biotechnology (VIR – Research Report), with a price target of $27.00. The company’s shares closed yesterday at $9.18.
According to TipRanks, Wang is a 5-star analyst with an average return of 9.0% and a 45.36% success rate. Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vir Biotechnology with a $32.00 average price target, a 248.58% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $15.00 price target.
Based on Vir Biotechnology’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.64 million and a GAAP net loss of $163.41 million. In comparison, last year the company earned a revenue of $374.56 million and had a net profit of $175.31 million
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VIR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vir Biotechnology (VIR) Company Description:
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
